May 1, 2007
I'm looking at the likely potential that Dendreon's DNDN provenge for prostate cancer will be approved by May 15th of this year. Yet the number of shares short has gone way up. I'm assuming these are borrowed shares that do not even reflect naked shorted shares. The question I have is...Wheather Provenge is approved or not, can enough shares be created out of thin air to drive Dendreon into the stone age without an approval or keep a lid on what the price might be if there is a likely approval?
If the answere is yes to either, isn't this stealing?
You might want to pay close attention to the goings on in Dendreon stock as May 15th approaches.